Houston innovators to know this week

who's who

This week's roundup of Houston innovators includes Navin Varadarajan of the University of Houston, Kelly Pracht of nVenue, and Atul Varadhachary of Fannin. Photos courtesy

Editor's note: Every week, I introduce you to a handful of Houston innovators to know recently making headlines with news of innovative technology, investment activity, and more. This week's batch includes two health tech innovators and a sportstech CEO.

Kelly Pracht, CEO and co-founder of nVenue

Kelly Pracht joins the Houston Innovators Podcast to discuss how she's expanded nVenue to new sports. Photo courtesy of nVenue

All though career technologist Kelly Pracht began her entrepreneurial journey with her favorite sport, baseball, she's recently expanded the data-backed, fan-engaging sports betting platform to new sports.

Pract, who spent nearly 20 years designing technologies at Hewlett Packard Enterprise, founded nVenue in 2019 after realizing that, while there's endless data and stats available in baseball, there's nothing that exists for fans to engage in that data in real time. So, she set out to build it herself.

At first, the platform launched as a direct-to-fans platform, but Pracht says on the Houston Innovators Podcast that the company pivoted to B-to-B amid its participation in the Comcast SportsTech accelerator.

"The industry was super hungry for fan engagement and sports betting, and we were one of the only companies that could do it," she says on the show. "We found this huge product-market fit of the whole industry wanting ways to engage and bet in real time." Read more.

Exclusive: 2 Houston health care institutions team up to develop cancer-fighting treatments

Fannin Partners and the University of Texas MD Anderson Cancer Center have teamed up to develop drugs based on Raptamer, the creation of Fannin company Radiomer Therapeutics. Photo via Getty Images

Two Houston organizations announced a new collaboration in a major move for Houston’s biotech scene.

Fannin Partners and the University of Texas MD Anderson Cancer Center have teamed up to develop drugs based on Raptamer, the creation of Fannin company Radiomer Therapeutics.

“Raptamers combine antibody level affinities with desirable physical and pharmacokinetic properties, and a rapid path to clinic,” Dr. Atul Varadhachary, CEO of Radiomer Therapeutics and Fannin managing partner, Varadhachary, explained to InnovationMap in May. “We are deploying this unique platform to develop novel therapies against attractive first-in-class oncology targets.” Read more.

Earlier this year, Varadhachary joined the Houston Innovators Podcast to discuss Fannin's innovation approach and contribution to medical development in Houston. Listen to the episode below.

Navin Varadarajan, M.D. Anderson Professor of William A. Brookshire Chemical and Biomolecular Engineering at University of Houston

The University of Houston's Navin Varadarajan explains that while COVID vaccines prevent advanced disease, they don’t prevent transmission. But he has a solution. Photo via UH

Since the force of COVID-19 hit globally in 2020, scientists have made efficient progress in the fight against it. As Dr. Navin Varadarajan puts it, vaccines have “allowed us to become a society again.”

And he should know, the M.D. Anderson Professor of William A. Brookshire Chemical and Biomolecular Engineering at University of Houston just published back-to-back studies for nasal sprays that combat viruses. One, the NanoSTING therapeutic, has proven effective in treating strains of SARS-CoV-2 and the flu virus. The other, NanoSTING-NS Pan-coronavirus Vaccine is targeted at preventing the transmission of multiple COVID variants altogether.

Why a nasal vaccine? Varadarajan explains that while COVID vaccines prevent advanced disease, they don’t prevent transmission.

“Intramuscular vaccines do not facilitate a component of peer immunity called mucosal immunity, which takes care of these points of entries, these wet surfaces, which can be of the nose and the wet surfaces of the nose, and so they don't prevent transmission,” he tells InnovationMap. “So I can be vaccinated, I pick up a small infection that's confined largely to my nostrils, and I can still pass it on to vulnerable people, the aged, the immunocompromised people who have all the drugs they're taking to fight other things, like cancer patients. And so for them, the vaccines tend to be less efficacious, and if I transfer it to them, unfortunately they can end up in a hospital, right? And so preventing transmission is the way to end this cycle.” Read more.

Fannin Partners and the University of Texas MD Anderson Cancer Center have teamed up to develop drugs based on Raptamer, the creation of Fannin company Radiomer Therapeutics. Photo via Getty Images

Exclusive: 2 Houston health care institutions team up to develop cancer-fighting treatments

collaboration station

Two Houston organizations announced a new collaboration in a major move for Houston’s biotech scene.

Fannin Partners and the University of Texas MD Anderson Cancer Center have teamed up to develop drugs based on Raptamer, the creation of Fannin company Radiomer Therapeutics.

“Raptamers combine antibody level affinities with desirable physical and pharmacokinetic properties, and a rapid path to clinic,” Dr. Atul Varadhachary, CEO of Radiomer Therapeutics and Fannin managing partner, Varadhachary, explained to InnovationMap in May. “We are deploying this unique platform to develop novel therapies against attractive first-in-class oncology targets.”

The pairing of Fannin and MD Anderson makes perfect sense. Researchers at the institution have already identified novel markers that they will target with both Raptamer-based drugs and radiopharmaceutical/radioligand therapies.

“MD Anderson and Fannin bring highly complementary capabilities to the identification of novel cancer targets and Raptamer-based drug discovery,” says Varadhachary in a press release. “Our collaboration will enable us to rapidly develop targeted therapeutics against novel targets, which we hope will offer hope to patients with progressive cancers.”

Early in this meeting of minds, researchers will focus on developing targeted radiopharmaceuticals — the Radiomers for which Varadhachary’s company is named — as well as targeted drug conjugates that utilize Raptamers. Raptamers are an innovative class of targeting vectors that combine a DNA oligonucleotide backbone with added peptide functionality, for oncology indications.

“We are committed to exceptional research that can help us further our understanding of cancer and develop impactful therapeutic options for patients in need,” says Timothy Heffernan, Ph.D., vice president and head of therapeutics discovery at MD Anderson. “Fannin’s Raptamer drug discovery platform represents an innovative new modality that offers the potential to enhance our portfolio of novel therapies, and we look forward to the opportunities ahead.”

Fannin and MD Anderson will design translational studies together and collaborate to select promising targets for drug discovery. This is a great deal for Fannin, which will retain commercialization rights for the assets that are developed. But MD Anderson won’t be left out; the institution is eligible to receive some payments based on the success of Radiomers and other Raptamer-based drugs developed through the collaboration.

Earlier this year, Varadhachary joined the Houston Innovators Podcast to discuss Fannin's innovation approach and contribution to medical development in Houston. Listen to the episode below.

Radiomer Therapeutics has launched under Fannin Partners with an undisclosed amount of seed funding. Photo via Getty Images

Early-stage cancer-fighting startup raises pre-seed, launches under Houston life science leader

ready to grow

Fannin Partners has done it again. The Houston-based life science development group behind medtech companies Procyrion and Allterum Therapeutics announced yesterday that it has launched Radiomer Therapeutics. With an undisclosed amount of pre-seed funding, Radiomer joins the $242 million-strong Fannin portfolio.

Radiomer uses Fannin’s proprietary Raptamer platform to target vectors and ligands for theranostic application. The cancer-fighting technology is a targeting agent that can address serious maladies including breast, lung, colorectal, prostate, and head and neck cancers.

And with Radiomer’s launch, Fannin is moving with its trademark aggressiveness. Lead programs expected to complete Phase 0 imaging/dosimetry trial(s) in cancer patients in the first quarter of next year. Those will be closely followed by therapeutic programs.

“Raptamers combine antibody level affinities with desirable physical and pharmacokinetic properties, and a rapid path to clinic,” Dr. Atul Varadhachary, CEO of Radiomer Therapeutics and Fannin managing partner, says in a press release. “We are deploying this unique platform to develop novel therapies against attractive first-in-class oncology targets.”

Varadhachary has operated Radiomer in stealth mode since its 2023 inception. However, Raptamer has been in the company’s portfolio since 2019. The new company has been using the platform to generate data with the rights to radiopharmaceutical applications for the past year.

“Our lead programs include Radiomers targeting both well-established and first-in-class cancer targets,” adds Dr. Phil Breitfeld, Radiomer’s chief medical officer. “Our imaging/dosimetry trials are designed to provide clinical evidence of tumor targeting and biodistribution information, positioning us to rapidly initiate a therapeutic program(s) if successful.”

For over a decade, Fannin has developed and supported promising life science innovations by garnering grant funding and using its team of expert product developers to build out the technology or treatment. The life science innovation timeline is very different from a software startup's, which can get to an early prototype in less than a year.

"In biotech, to get to that minimally viable product, it can take a decade and tens of millions of dollars," Varadhachary said on the Houston Innovators Podcast earlier this year.

This week's roundup of Houston innovators includes Aziz Gilani of Mercury, Yaxin Wang of the Texas Heart Institute, and Atul Varadhachary of Fannin Innovation. Photos courtesy

3 Houston innovators to know this week

who's who

Editor's note: Welcome to another Monday edition of Innovators to Know. Today I'm introducing you to three Houstonians to read up about — three individuals behind recent innovation and startup news stories in Houston as reported by InnovationMap. Learn more about them and their recent news below by clicking on each article.


Aziz Gilani, managing director at Mercury

Aziz Gilani, managing director at Mercury, joins the Houston Innovators Podcast. Photo via LinkedIn

Aziz Gilani's career in tech dates back to when he'd ride his bike from Clear Lake High School to a local tech organization that was digitizing manuals from mission control. After years working on every side of the equation of software technology, he's in the driver's seat at a local venture capital firm deploying funding into innovative software businesses.

As managing director at Mercury, the firm he's been at since 2008, Gilani looks for promising startups within the software-as-a-service space — everything from cloud computing and data science and beyond.

"Once a year at Mercury, we sit down with our partners and talk about the next investment cycle and the focuses we have for what makes companies stand out," Gilani says on the Houston Innovators Podcast. "The current software investment cycle is very focused on companies that have truly achieved product-market fit and are showing large customer adoption." Read more.


Yaxin Wang, director of the Texas Heart Institute's Innovative Device & Engineering Applications Lab

The project is funded by a four-year, $7.8 million grant. THI will use about $2.94 million of that to fund its part of the research. Photo via texasheart.org

The United States Department of Defense has awarded a grant that will allow the Texas Heart Institute and Rice University to continue to break ground on a novel left ventricular assist device (LVAD) that could be an alternative to current devices that prevent heart transplantation and are a long-term option in end-stage heart failure.

The grant is part of the DOD’s Congressionally Directed Medical Research Programs (CDMRP). It was awarded to Georgia Institute of Technology, one of four collaborators on the project that will be designed and evaluated by the co-investigator Yaxin Wang. Wang is part of O.H. “Bud” Frazier’s team at Texas Heart Institute, where she is director of Innovative Device & Engineering Applications Lab. The other institution working on the new LVAD is North Carolina State University.

The project is funded by a four-year, $7.8 million grant. THI will use about $2.94 million of that to fund its part of the research. As Wang explained to us last year, an LVAD is a minimally invasive device that mechanically pumps a person’s own heart. Frazier claims to have performed more than 900 LVAD implantations, but the devices are far from perfect. Read more.

Atul Varadhachary, managing director of Fannin Innovation

Atul Varadhachary also serves as CEO and president of Allterum Therapeutics. Photo via LinkedIn

Allterum Therapeutics, a Houston biopharmaceutical company, has been awarded a $12 million product development grant from the Cancer Prevention and Research Institute of Texas (CPRIT).

The funds will support the clinical evaluation of a therapeutic antibody that targets acute lymphoblastic leukemia (ALL), one of the most common childhood cancers.

However, CEO and President Atul Varadhachary, who's also the managing director of Fannin Innovation, tells InnovationMap, “Our mission has grown much beyond ALL.” Read more.

The funds will support the clinical evaluation of a therapeutic antibody that targets acute lymphoblastic leukemia, one of the most common childhood cancers. Photo via Getty Images

Houston startup scores $12M grant to support clinical evaluation of cancer-fighting drug

fresh funding

Allterum Therapeutics, a Houston biopharmaceutical company, has been awarded a $12 million product development grant from the Cancer Prevention and Research Institute of Texas (CPRIT).

The funds will support the clinical evaluation of a therapeutic antibody that targets acute lymphoblastic leukemia (ALL), one of the most common childhood cancers.

However, CEO and President Atul Varadhachary, who's also the managing director of Fannin Innovation, tells InnovationMap, “Our mission has grown much beyond ALL.”

The antibody, called 4A10, was invented by Scott Durum PhD and his team at the National Cancer Institute (NCI). Licensed exclusively by Allterum, a company launched by Fannin, 4A10 is a novel immunotherapy that utilizes a patient’s own immune system to locate and kill cancer cells.

Varadhachary explained that while about 80 percent of patients afflicted with ALL have the B-cell version, the other 20 percent suffer from T-cell ALL.

“Because the TLL population is so small, there are really no approved, effective drugs for it. The last drug that was approved was 18 or 19 years ago,” the CEO-scientist said. 4A10 addresses this unmet need, but also goes beyond it.

Because 4A10 targets CD127, also known as the interleukin-7 receptor, it could be useful in the treatment of myriad cancers. In fact, the receptor is expressed not just in hematological cancers like ALL, but also solid tumors like breast, lung, and colorectal cancers. There’s also “robust data,” according to Varadhachary for the antibody’s success against B-cell ALL, as well as many other cancers.

“Now what we're doing in parallel with doing the development for ALL is that we're continuing to do additional preclinical work in these other indications, and then at some point, we will raise a series A financing that will allow us to expand markets into things which are much more commercially attractive,” Varadhachary explains.

Why did they go for the less commercially viable application first? As Varadhachary put it, “The Fannin model is to allow us to go after areas which are major unmet medical needs, even if they are not necessarily as attractive on a commercial basis.”

But betting on a less common malady could have a bigger payoff than the Allterum team originally expected.

Before the new CPRIT grant, Allterum’s funding included a previous seed grant from CPRIT of $3 million. Other funds included an SBIR grant from NCI, as well as another NCI program called NExT, which deals specifically with experimental therapies.

“To get an antibody from research into clinical testing takes about $10 million,” Varadhachary says. “It's an expensive proposition.”

With this, and other nontraditional financing, the company was able to take what Varadhachary called “a huge unmet medical need but a really tiny commercial market” and potentially help combat a raft of other childhood cancers.

“That's our vision. It's not economically hugely attractive, but we think it's important,” says Varadhachary.

Atul Varadhachary is the managing director of Fannin Innovation. Photo via LinkedIn

Procyrion has announced the closing of its series E round of funding. Photo via Getty Images

Houston medical device company secures $57.7M to fund journey to FDA approval, commercialization

fresh funding

Houston-born and bred medical device company, Procyrion, has completed its series E with a raise of $57.7 million, including the conversion of $10 million of interim financing.

Procyrion is the company behind Aortix, a pump designed to be placed in the descending thoracic aorta of heart failure patients, which has been shown to improve cardiac performance in seriously ill subjects. The money raised will allow the company to proceed with a the DRAIN-HF Study, a pivotal trial that will be used for eventual FDA approval and commercialization.

The Aortix is the brainchild of Houston cardiologist Reynolds Delgado. According to Procyrion’s CSO, Jace Heuring, Delgado, gained some of his experience with devices for the heart working with legendary Texas Heart Institute surgeon O.H. “Bud” Frazier. He filed his first patents related to the Aortix in 2005.

Heuring says that the first prototypes were built in 2011, followed by the final design in 2018. CEO Eric Fain, a California-based MD and with more than 30 years in the medical device industry, joined the company in 2018 ahead of the final design, primed to bring Aortix to the public. He visits the company’s Houston headquarters, across the street from Central Market, on a regular basis.

The device’s pilot study of 18 patients was completed in 2022. Those encouraging results paved the way for the current study, which will include an enrollment of 134 patients. The randomized study will seek to treat patients with acute decompensated heart failure. Half will be treated with standard-of-care therapy, the other half will be catheterized with an Aortix pump. A separate arm of the study will seek to treat end-stage heart failure patients who would otherwise be deemed too sick for either a transplant or an LVAD permanent pump. Fort-five healthcare centers in the United States will participate, including Texas Heart Institute.

“One of the key characteristics is [the patients] are retaining a lot of fluid,” explains Heuring in a video interview. “And when I say a lot, I mean it could be 25 or 30 or 40 pounds of fluid or more. When we put our pump in, one of the main goals is to reduce that fluid load.”

On average, about 11 liters of fluid came off of each patient. Many of those end-stage patients had previously been considered for both a heart and kidney transplant, but after using the Aortix, their kidneys responded so well that they were able to get only the heart transplant.

“These patients really are in dire straits and come into the hospital and today the only proven therapy to help these patients is to administer high doses of intravenous diuretic and some other cardiac drugs and in about 25 percent of patients those therapies are ineffective,” says Fain.

If Aortix gains approval, these sickest of the sick, usually consigned to hospice care, will have hope.

Thanks to the Series E, led by Houston’s Fannin Partners, returning investors, including Bluebird Ventures, the Aortix is inching closer to commercialization. Besides funding the DRAIN-HR study, Procyrion will also use the funds for internal programs to improve product manufacturability. One more step towards meaning advanced heart failure may not always be a death sentence.

Last month, Atul Varadhachary, managing director of Fannin, joined the Houston Innovators Podcast and alluded to Procyrion's raise. The company was born out of Fannin and still resides in the same building as Fannin.

Aortix is a pump designed to be placed in the descending thoracic aorta of heart failure patients. Photo via Procyrion

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Diversity-focused sports tech accelerator opens applications to Houston innovators for the first time

apply now

A global organization has announced it's opening applications to its equity-focused sports tech accelerator to Houston founders for the first time.

Thanks to a collaboration with Impact Hub and Black Ambition, the adidas Community Lab has expanded its footprint and is now accepting applicants from new markets, including Houston, Toronto, Los Angeles, Atlanta, and New York, for its 2024-2025 cohort.

The initiative, which has been running for three years, has a goal of supporting Black and Latino/a/e founders with mentorship, pitch training, event programming, and networking. The eight-month program also has $75,000 in grant funding to dole out to participants as well.

“As Community Lab enters its third year, we are thrilled to cultivate a larger cohort of social entrepreneurs who share our vision of removing barriers to accessing sport for the communities we collectively serve,” Ayesha Martin, senior director of adidas Purpose, says in a news release.

Both the global organization of Impact Hub and the local group, Impact Hub Houston, are involved in the collaboration.

“Impact Hub is thrilled to partner and support this third iteration of adidas Community Lab, empowering visionary leaders who are advancing SDG3 —Good Health and Wellbeing — and SDG10 — Reduced Inequalities," Michelle Avalos, co-founder of Impact Hub Houston, adds. Together, we’re helping entrepreneurs create equitable access to sports and foster healthier, more inclusive communities for all."

Applications are open online now until September 23.

Founded by Pharrell Williams, Black Ambition will also collaborate with the program this year on key programing sessions. The organization invests funding and resources into Black and Hispanic entrepreneur-founded startups.

"Black Ambition was founded to create the space, bespoke opportunities and relationships needed for underrepresented founders to excel, uninterrupted. We are excited to partner with adidas Purpose to extend elements of our renowned, global founder support model to social impact entrepreneurs positively transforming their communities through sports and wellness," says Jermeen Sherman, managing director at Black Ambition.

City of Houston grants $100,000 to 10 innovative arts organizations

civic support

Ten Houston individuals and nonprofits are beneficiaries of grants totaling $100,000 for efforts to furthers cultural tourism and resilience throughout the City of Houston.

The Mayor’s Office of Cultural Affairs (MOCA) awarded the funds through the Initiative, a competitive grant program administered by Houston Arts Alliance (HAA) and funded by a portion of the city’s Hotel Occupancy Tax.

The application period is open three times annually and grant funding falls into three categories: Art + Neighborhood Cultural Destinations, Art + Disaster Resilience Awareness, and Art + Conference Tourism.

Here is a look at the winners and the projects that will be created with these grants.

Art + Conference Tourism

Contemporary Arts Museum Houston
This week, from September 16-19, the museum, in partnership with Houston Freedmen’s Town Conservancy (HFTC) and artist Theaster Gates, hosts Houston’s edition of the renowned Black Artists Retreat (B.A.R). The initiative explores the concept of “Black Land Ownership and Space: Black Stabilization and Determination." The four-day event brings together speakers, panelists, and experts from Houston and across the country to elevate and inspire the brain trust in local Black and BIPOC artists, creatives, and intellectuals. Programming occurs in Houston Freedmen’s Town, POST Houston, and CAMH.

One Sample Cultural Foundation
The organization will use its grant to produce the Ethnography of Afro-Venezuelan Music, a multidisciplinary educational conference that includes videos, music, and dance that exploring the syncretism of African culture and European religious practices in Venezuela through music. This free event will take place twice — at the Institute of Hispanic Culture of Houston on October 10 and at Teatro Bilingüe de Houston on April 13, 2025. The project aims to strengthen ties between the African American and Venezuelan communities and promote a dynamic cultural exchange.

SoulSista Art Foundation
The organization hosts a conference highlighting Houston’s contributions to the new music business at Houston Warehouse Studio on November 11. Free and open to the general public, it will include performances from selected poets and Afrobeats artists who have been recognized over the years in Houston, along with a DJ and food trucks. Donations will be accepted.

Art + Neighborhood Cultural Destinations

DaCamera
The music organization will use its grant for a series of jazz concerts at the historic El Dorado Ballroom in Third Ward. DaCamera at The Eldorado: Rising Jazz Stars features up-and-coming jazz artists from around the country, providing a new opportunity for Houstonians to experience the next generation of outstanding jazz talent. Concerts begin in October and run through May 2025. All performances will be pay-what-you-can.

Dance Afrikana
A curated exhibition, digital dance archive, and a book are planned as part of the organization's Black Dance in Texas multidisciplinary project. Documenting the rich history of Black dance in the state, this project is an extension of the research project by Dance Afrikana’s founder and Scholar-in-Residence for Rice University’s CERCL Program at the African American History Research Center Gregory Campus.

Norma Jo Thomas
The composer's original musical, Carol of the Bells, will have its world premiere on December 14 at the C. Lee Turner Performing Arts Center on the campus of Lone Star College. The holiday offering is part of Thomas' ongoing tradition to bring cultural programming to the community, and is part of an Acres Homes community collaboration.

The Pilot Dance Project

Celebrated Houston-based choreographer Cynthia Garcia presents Loteria, which brings to life the characters of the traditional Mexican board game. In an urban landscape of constant gentrification, often cultural signifiers, customs, and traditions are left behind to show the legacies of cultural communities. The work will be performed at two major cultural events in gentrified neighborhoods that have histories as Mexican and Mexican American neighborhoods, MECA’s Day of the Dead Festival in October and the MD Anderson YMCA’s annual posada in Near Northside in December.

University of Houston Foundation
Seven-time Grammy Award-winner Terence Blanchard will engage communities from Third Ward and downtown Houston in a series of events. In addition to performing a concert, the jazz legend will collaborate with University of Houston and University of Houston-Downtown students. Performance will take place November 7, 8, and 10 at the Wortham Theater Center or at the University of Houston Moores School of Music. A fireside chat and workshop are also part of the visit.

Art + Resilience Awareness

Group Acorde
The organization's Batimento Cardiaco is a new work that depicts Houstonians' mental health before, during, and after a natural disaster occurs. It will premiere at the MATCH October 3 and 4, and feature musicians, two contemporary dance choreographers, and a visual artist who've collaborated on this important work. Sets and costumes are made of recyclable materials. A discussion will follow the performance. Rehearsals streamed on Group Acorde's social media will give audiences a look at the work as it develops.

Lance Flowers
The artists solo exhibit, Take Me As I Am, takes place simultaneously at the Hogan Brown Gallery in Third Ward and Yale University’s Institute for Sacred Music. It's a collection of new 2D works, videography, music, and photography pieces highlighting Third Ward and its community, and all the materials used will be gathered from the Third Ward. It's curated by gallery director Robert Hodge. The Yale portion of this show has received its own funding.

------

This article originally ran on CultureMap.

How to prepare your business for severe weather, according to this Houston expert

guest column

Unprecedented severe weather events are becoming more frequent and intense. Proactive business planning is critical to navigating what Mother Nature has in store for us.

In Houston, severe weather can impact operations any time of year, not just hurricane season, so now is the time to incorporate any fresh lessons learned during Hurricane Beryl into your plans. Employers are responsible for safeguarding their employees and assets during these emergencies, which requires establishing an emergency action plan as a foundation of preparedness.

Develop an Emergency Action Plan

If your business does not have an emergency action plan (EAP), today is the perfect time to start it so you are prepared with a response strategy. This clearly written plan is a blueprint for how your business will react and protect employees when severe weather strikes. The more detailed the EAP, the better you and your employees will respond in a time of crisis. Within the EAP, it is important to outline specific protocols, designate key roles and responsibilities and establish communication channels for employees and clients. As power can be an issue during severe weather events, outlining various communication channels is helpful.

Identify Key Employees

During an emergency, you need to know who has the authority to make the decisions that impact your employees and your business. The designated person needs to assess the situation, determine whether employees should work remotely or shelter in place, and communicate these decisions clearly and quickly. This person is usually on the leadership team and can be trusted to make clear decisions, act promptly and communicate effectively to mitigate undue risks.

Implement Regular Emergency Training

Practice makes perfect. A plan on paper is the first step, but it must be practiced and drilled so everyone knows what to do, asks questions and makes any needed adjustments, all when the stakes are not as high. Familiarity with emergency procedures through periodic training and drills allows employees to practice evacuation routes, assembly points and safety protocols.Incorporating local emergency responders in safety drills familiarizes employees with the roles and responsibilities of each group. Through this emergency training, your teams will become confidently prepared to calmly respond to emergencies.

Provide a Swift and Orderly Response

Proactively thinking through and planning for location-specific emergency situations allows business owners to mitigate risks associated with severe weather events and quickly respond when a crisis strikes. When your business is prepared, there is less downtime and disruption to business operations, it protects physical assets, and most importantly, it prioritizes the safety and well-being of employees.

Houston experiences a wild mix of severe weather situations, which makes proactive business planning and preparedness even more critical. Prioritizing EAP development and implementation, designating responsible decision-makers, conducting regular training and drills, and ensuring clear communication channels sets the stage for a resilient organization in severe weather. Additionally, establishing a clear EAP helps foster a culture of safety and readiness that can significantly protect lives and livelihoods during times of crisis.

———

Ray Brock is a director of safety services with Insperity, a leading provider of human resources offering the most comprehensive suite of scalable HR solutions available in the marketplace.

This article originally ran on EnergyCapital.

View All Listings